Back to Awarded Treatment Trials
Awarded Trial: 01-106
Grant ID
01-106
Illness
Bipolar Disorder
Primary Drug/Intervention
Chromium Picolinate
Primary Dosage
600 mg - 800 mg
Secondary Drug Intervention
N/A
Secondary Dosage
N/A
Other Drug/Intervention
N/A
Other Dosage
N/A
Status
Completed
Investigator
Amann
Sample Size
30
Duration of Study Period for Each Subject
3 weeks, with optional 2 year follow up
Outcome Measurements
CGI-BP, HAM-D, MADRS, YMRS
Results
At enrollment 23 patients had a depressive syndrome and seven were euthymic. Depressed patients experienced a 26% reduction in HAM-D scores and a similar reduction in MADRS scores. About 30% of patients were considered to be responders (>50% reduction in depression ratings). Seven patients remained on the treatment for one year and four for two years. The number of effective episodes for these patients decreased relative to the period prior to study entry.
Publication
N/A
Link
N/A
PI Name
Benedikt Amann
Degree
MD
Center
Dept. of Psychiatry and Psychotherapy
Institution
Ludwig-Maximillians Universitaet
Address
Nussbaumstr. 7, Ward C2
City or Town
Munich
State or Province
N/A
Zip or Postal Code
80336
Country
Germany
Email Address
benedikt.amann@med.uni-muenchen.de